Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
Completed · Phase 2 · NCT07264517
Conditions: Dry Eye Disease
At a glance
- Research payments reported, 2025
- $3,375
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 103
About the trial
- Sponsor
- Instituto Grifols, S.A.
- Tested
- GRF312 5% (drug), Placebo Comparator (other)
- Dates
- Started 2025-11-03; completion 2026-05-20
- Results posted
- Not yet
This is a Phase 2, multi-site, double-masked, randomized, vehicle-controlled, study designed to evaluate the safety, tolerability, and efficacy in adult participants with DED.
From ClinicalTrials.gov, last updated 2026-06-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Instituto Grifols, S.a. reported $3,375 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Midwest Cornea Associates $3,375
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.